![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RPL12 |
Gene summary for RPL12 |
![]() |
Gene information | Species | Human | Gene symbol | RPL12 | Gene ID | 6136 |
Gene name | ribosomal protein L12 | |
Gene Alias | L12 | |
Cytomap | 9q33.3 | |
Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | P30050 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6136 | RPL12 | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 3.54e-48 | 2.06e+00 | -0.1433 |
6136 | RPL12 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 2.78e-56 | 1.95e+00 | -0.1833 |
6136 | RPL12 | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 1.46e-22 | 3.16e+00 | -0.23 |
6136 | RPL12 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 6.97e-22 | 3.46e+00 | -0.23 |
6136 | RPL12 | 047563_1562-all-cells | Human | Prostate | BPH | 3.02e-52 | -4.19e-01 | 0.0791 |
6136 | RPL12 | 048752_1579-all-cells | Human | Prostate | BPH | 1.25e-99 | -6.07e-01 | 0.1008 |
6136 | RPL12 | 052095_1628-all-cells | Human | Prostate | BPH | 6.56e-41 | -4.53e-01 | 0.1032 |
6136 | RPL12 | 052097_1595-all-cells | Human | Prostate | BPH | 1.60e-92 | -7.46e-01 | 0.0972 |
6136 | RPL12 | 052099_1652-all-cells | Human | Prostate | BPH | 5.39e-78 | -7.38e-01 | 0.1038 |
6136 | RPL12 | Dong_P1 | Human | Prostate | Tumor | 7.27e-60 | 1.91e-01 | 0.035 |
6136 | RPL12 | Dong_P3 | Human | Prostate | Tumor | 4.25e-19 | 1.53e-01 | 0.0278 |
6136 | RPL12 | Dong_P5 | Human | Prostate | Tumor | 2.08e-05 | 7.94e-02 | 0.053 |
6136 | RPL12 | Dong_P6 | Human | Prostate | Tumor | 6.03e-03 | 9.04e-02 | 0.0371 |
6136 | RPL12 | P7 | Human | Prostate | Tumor | 1.67e-41 | 2.42e+00 | -0.1025 |
6136 | RPL12 | P9 | Human | Prostate | Tumor | 3.05e-13 | 6.74e-01 | -0.0285 |
6136 | RPL12 | P10 | Human | Prostate | Tumor | 6.98e-14 | 2.09e+00 | -0.0902 |
6136 | RPL12 | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 6.61e-19 | -7.48e-01 | 0.1557 |
6136 | RPL12 | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 4.94e-34 | -1.08e+00 | 0.159 |
6136 | RPL12 | GSM5353217_PA_PB1A_Pool_2_S107_L004 | Human | Prostate | Tumor | 5.35e-18 | -9.47e-01 | 0.156 |
6136 | RPL12 | GSM5353218_PA_PB1B_Pool_1_2_S74_L003 | Human | Prostate | Tumor | 5.32e-28 | -1.04e+00 | 0.1479 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
GO:000218124 | Breast | DCIS | cytoplasmic translation | 82/1390 | 148/18723 | 2.21e-53 | 1.25e-49 | 82 |
GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
GO:00021811 | Colorectum | SER | cytoplasmic translation | 102/2897 | 148/18723 | 1.38e-48 | 8.49e-45 | 102 |
GO:00021812 | Colorectum | MSS | cytoplasmic translation | 108/3467 | 148/18723 | 1.78e-47 | 1.11e-43 | 108 |
GO:00021813 | Colorectum | MSI-H | cytoplasmic translation | 100/1319 | 148/18723 | 1.50e-79 | 8.31e-76 | 100 |
GO:00021814 | Colorectum | FAP | cytoplasmic translation | 76/2622 | 148/18723 | 3.31e-27 | 2.03e-23 | 76 |
GO:00021815 | Colorectum | CRC | cytoplasmic translation | 70/2078 | 148/18723 | 1.53e-28 | 9.16e-25 | 70 |
GO:000218116 | Endometrium | AEH | cytoplasmic translation | 104/2100 | 148/18723 | 1.01e-64 | 6.07e-61 | 104 |
GO:000218117 | Endometrium | EEC | cytoplasmic translation | 104/2168 | 148/18723 | 2.53e-63 | 1.52e-59 | 104 |
GO:000218127 | Esophagus | HGIN | cytoplasmic translation | 108/2587 | 148/18723 | 1.70e-60 | 1.02e-56 | 108 |
GO:01400534 | Esophagus | HGIN | mitochondrial gene expression | 27/2587 | 108/18723 | 1.34e-03 | 1.57e-02 | 27 |
GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
GO:014005313 | Esophagus | ESCC | mitochondrial gene expression | 93/8552 | 108/18723 | 1.96e-18 | 2.03e-16 | 93 |
GO:00009592 | Esophagus | ESCC | mitochondrial RNA metabolic process | 39/8552 | 49/18723 | 1.20e-06 | 1.49e-05 | 39 |
GO:00021817 | Liver | NAFLD | cytoplasmic translation | 93/1882 | 148/18723 | 1.44e-55 | 8.41e-52 | 93 |
GO:000218112 | Liver | Cirrhotic | cytoplasmic translation | 120/4634 | 148/18723 | 2.95e-47 | 1.85e-43 | 120 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPL12 | deletion | Frame_Shift_Del | novel | c.348_358delNNNNNNNNNNN | p.Met116IlefsTer11 | p.M116Ifs*11 | P30050 | protein_coding | TCGA-E9-A1N9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
RPL12 | SNV | Missense_Mutation | c.257N>G | p.Lys86Arg | p.K86R | P30050 | protein_coding | deleterious(0.01) | benign(0.229) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
RPL12 | SNV | Missense_Mutation | novel | c.494N>T | p.Ser165Ile | p.S165I | P30050 | protein_coding | deleterious(0) | possibly_damaging(0.796) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RPL12 | SNV | Missense_Mutation | novel | c.43N>A | p.Leu15Met | p.L15M | P30050 | protein_coding | deleterious(0.04) | possibly_damaging(0.686) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPL12 | SNV | Missense_Mutation | c.356N>A | p.Arg119Gln | p.R119Q | P30050 | protein_coding | tolerated(0.25) | benign(0.007) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD | |
RPL12 | SNV | Missense_Mutation | novel | c.151G>A | p.Gly51Ser | p.G51S | P30050 | protein_coding | tolerated(0.26) | benign(0.006) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPL12 | SNV | Missense_Mutation | novel | c.476N>T | p.Ala159Val | p.A159V | P30050 | protein_coding | tolerated(0.19) | benign(0.007) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
RPL12 | SNV | Missense_Mutation | novel | c.271N>T | p.Asp91Tyr | p.D91Y | P30050 | protein_coding | deleterious(0.02) | possibly_damaging(0.611) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPL12 | SNV | Missense_Mutation | rs199572941 | c.457N>A | p.Asp153Asn | p.D153N | P30050 | protein_coding | deleterious(0.02) | benign(0.053) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPL12 | SNV | Missense_Mutation | c.170N>A | p.Arg57Lys | p.R57K | P30050 | protein_coding | tolerated(0.36) | benign(0.026) | TCGA-HU-A4H8-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | didox | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |